Sebi bans Celestial Biolabs, 2 others from the capital mkts for 10 yrs

Regulator Sebi Friday barred Celestial Biolabs as well as its chairman A N Singh and wife Padma Singh from the capital markets for 10 years for fabricating the company’s sales figures and making false disclosures. Besides, the capital markets watchdog has restrained Celestial Biolabs’ statutory auditor Lakshmi Purna & Associates for not being cautious and careful while certifying the annual accounts of the firm.

The regulator carried out a probe to ascertain whether books of accounts of the company were manipulated by way of fictitious transactions to project a rosy picture of the company to the shareholders in 2010-11 and 2011-12 and to see whether there was any violation of the provisions of PFTUP (Prohibition of Fraudulent and Unfair Trade Practices) norms.

Sebi found that the company employed deceptive devices by projecting inflated sales in Bio-IT and had adopted dubious and inconsistent practices in drawing up accounts for manipulating the financial results of the firm to present a rosy picture to its shareholders and to the public at large.

According to the regulator, the firm showed fake sales amounting to Rs 677 lakh in 2010-11 and Rs 395 lakh in 2011-12 and the same was disclosed in its annual reports.

It further said that the couple and Purna & Associates by playing their respective roles in this elaborate scheme, “adopted a fraudulent device and artifice to defraud the genuine shareholders of the company by first falsely portraying sales transactions with pharma companies in Bio-IT services and then by treating the purported bad debts under the heading Product Development Expenditure”.

The couple, being the directors of the company, “have failed in their duty to exercise due care and diligence and were part of the deceptive device / scheme to fabricate the sales figures in Bio-IT and making false disclosures,” Sebi said in an order.

Currently, they are part of the promoters group of Celestial Biolabs, as per the latest update with stock exchanges.

By indulging in such things, the company and its directors violated the provision of PFUTP Regulations and Listing Obligations and Disclosure Requirement.

Accordingly, the regulator has barred Celestial Biolabs, AN Singh and Padma Singh from buying, selling or otherwise dealing in the securities market for a period of 10 years.

“Lakshmi Purna & Associates shall not directly or indirectly issue any certificate of audit of listed companies…for a period of five years,” it added.

  • Related Posts

    Lilly launches Mounjaro KwikPen in India

    Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Sakeena Itoo reviews performance, functioning of JKMSCL

    Sakeena Itoo reviews performance, functioning of JKMSCL

    Dr Arun Prasad gets Recognition in London for Global Impact

    Dr Arun Prasad gets Recognition in London for Global Impact

    Karnataka State Information Commission slaps ₹1 lakh penalty on BDA official for failing to provide information

    Karnataka State Information Commission slaps ₹1 lakh penalty on BDA official for failing to provide information

    NSQ reporting nearly doubles in 2025, buoyed by greater state participation

    NSQ reporting nearly doubles in 2025, buoyed by greater state participation

    Two Gyms In Firozabad Raided, Seize 20 Mephentermine Injections Amid Health Concerns

    Two Gyms In Firozabad Raided, Seize 20 Mephentermine Injections Amid Health Concerns

    Delhi Drugs Control Department Seizes Insulin Stock Worth Rs 20.06 Lakh

    Delhi Drugs Control Department Seizes Insulin Stock Worth Rs 20.06 Lakh